0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

Corneal Cupremia in Multiple Myeloma: A Clinicopathologic Correlation FREE

Rona Z. Silkiss, MD; Dustin Pomerleau, MD; Andrew Sorenson, MD; David Vastine, MD; J. Brooks Crawford, MD
Arch Ophthalmol. 2008;126(7):1005-1006. doi:10.1001/archopht.126.7.1005.
Text Size: A A A
Published online

We describe the study of an eye from a patient with corneal cupremia secondary to multiple myeloma. An intercurrent episode of mucormycosis necessitated removal of this individual's eye, enabling this unique study.

A 71-year-old white woman with an 8-year history of refractory multiple myeloma had blurred vision. Her best-corrected visual acuity was 20/30 OU. In both eyes, the cornea manifested a remarkable golden-brown, metallic sheen that on slitlamp examination was determined to be at the level of the Descemet membrane (Figure 1). The remainder of her examination disclosed no abnormalities. Several months later, the patient's vision rapidly decreased and she was diagnosed with mucormycosis of the orbit and sinus. Despite aggressive sinus and orbit débridement as well as the use of antifungal agents, the patient required exenteration. The exenteration specimen provided a unique opportunity to study her eye.

Place holder to copy figure label and caption
Figure 1.

Slitlamp image of the patient's left eye, demonstrating a golden-brown sheen at the level of the Descemet membrane secondary to corneal copper deposition.

Graphic Jump Location

Light microscopy demonstrated slightly granular, tan pigmentation of the anterior portion of the Descemet membrane in the central cornea. Copper-specific staining with rubeanic acid showed highly positive staining of the central cornea, primarily in the anterior Descemet membrane with some additional granular staining of the posterior Descemet membrane (Figure 2). Similar stains of the midperipheral and peripheral cornea revealed that copper was absent from these regions. No copper deposition was noted in the lens capsule as has been previously reported.16

Place holder to copy figure label and caption
Figure 2.

Copper-specific staining of the central cornea highlights the areas of copper deposition. Deposits were seen primarily in the anterior portion of the Descemet membrane, with a small amount of staining in the posterior Descemet membrane as well (rubeanic acid, original magnification ×100).

Graphic Jump Location

Deposition of copper in ocular tissues has been reported in the context of multiple myeloma,13 IgG monoclonal gammopathy associated with pulmonary carcinoma,4 and benign monoclonal gammopathy of undetermined significance.5 The unifying factor in these conditions appears to be the presence of IgG light chains that bind copper with an unusually high affinity. Both κ and λ light chains have been reported to bind copper. Patients with these conditions have markedly elevated serum copper levels and normal to slightly elevated serum ceruloplasmin levels (in contrast to the low ceruloplasmin levels found in Wilson disease). Copper deposits have been reported in the cornea at the level of the Descemet membrane, within the anterior and posterior lens capsule, and within the trabecular meshwork.13,5

In multiple myeloma, the copper deposition is central and tends to spare the limbal region. The central cornea manifests a remarkable iridescent sheen secondary to fine, metallic particles at the level of the Descemet membrane. The diffuse central sheen may be supplemented by a radial pattern of spokes but is universally reported to stop within 2 to 3 mm of the limbus.

Various theories attempt to explain why copper is deposited centrally in monoclonal gammopathy and peripherally in Wilson disease. It has been hypothesized that the corneal copper is derived from the limbal circulation in Wilson disease, whereas in multiple myeloma the deposition is secondary to elevated levels of copper in the aqueous humor.1

Interestingly, monoclonal IgG and IgG light chains appear to bind copper in these disease states but are not known to do so in vitro. In at least 1 case, the copper-carrying protein was sequenced in an attempt to determine whether it shared the N-terminal Asp-Ala-His amino acid sequence known to bind copper in albumin, but no such sequence was found.5 Sequences as simple as Gly-His are capable of binding copper under certain circumstances, especially if they are repeated, rendering it difficult to determine the location of a potential binding site based on sequence alone. Myeloma protein is known to accumulate in the eye as an amyloid, and although individual myeloma proteins do not appear to bind copper, closely packed myeloma proteins may be able to do so.

Correspondence: Dr Pomerleau, Department of Ophthalmology, California Pacific Medical Center, 2340 Clay St, Fifth Floor, San Francisco, CA 94115 (dustypomerleau@gmail.com).

Financial Disclosure: None reported.

Ellis  PP Ocular deposition of copper in hypercupremia. Am J Ophthalmol 1969;68 (3) 423- 427
PubMed
Lewis  RAFalls  HFTroyer  DO Ocular manifestations of hypercupremia associated with multiple myeloma. Arch Ophthalmol 1975;93 (10) 1050- 1053
PubMed Link to Article
Hawkins  ASStein  RMGaines  BIDeutsch  TA Ocular deposition of copper associated with multiple myeloma. Am J Ophthalmol 2001;131 (2) 257- 259
PubMed Link to Article
Martin  NFKincaid  MCStark  WJ  et al.  Ocular copper deposition associated with pulmonary carcinoma, IgG monoclonal gammopathy and hypercupremia: a clinicopathologic correlation. Ophthalmology 1983;90 (1) 110- 116
PubMed Link to Article
Probst  LEHoffman  ECherian  MG  et al.  Ocular copper deposition associated with benign monoclonal gammopathy and hypercupremia. Cornea 1996;15 (1) 94- 98
PubMed Link to Article
Garg  SJampol  LMLewis  RAPenner  JA Corneal copper deposition secondary to a variant of multiple myeloma: 30-year catamnesis. Arch Ophthalmol 2006;124 (1) 130- 132
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Slitlamp image of the patient's left eye, demonstrating a golden-brown sheen at the level of the Descemet membrane secondary to corneal copper deposition.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Copper-specific staining of the central cornea highlights the areas of copper deposition. Deposits were seen primarily in the anterior portion of the Descemet membrane, with a small amount of staining in the posterior Descemet membrane as well (rubeanic acid, original magnification ×100).

Graphic Jump Location

Tables

References

Ellis  PP Ocular deposition of copper in hypercupremia. Am J Ophthalmol 1969;68 (3) 423- 427
PubMed
Lewis  RAFalls  HFTroyer  DO Ocular manifestations of hypercupremia associated with multiple myeloma. Arch Ophthalmol 1975;93 (10) 1050- 1053
PubMed Link to Article
Hawkins  ASStein  RMGaines  BIDeutsch  TA Ocular deposition of copper associated with multiple myeloma. Am J Ophthalmol 2001;131 (2) 257- 259
PubMed Link to Article
Martin  NFKincaid  MCStark  WJ  et al.  Ocular copper deposition associated with pulmonary carcinoma, IgG monoclonal gammopathy and hypercupremia: a clinicopathologic correlation. Ophthalmology 1983;90 (1) 110- 116
PubMed Link to Article
Probst  LEHoffman  ECherian  MG  et al.  Ocular copper deposition associated with benign monoclonal gammopathy and hypercupremia. Cornea 1996;15 (1) 94- 98
PubMed Link to Article
Garg  SJampol  LMLewis  RAPenner  JA Corneal copper deposition secondary to a variant of multiple myeloma: 30-year catamnesis. Arch Ophthalmol 2006;124 (1) 130- 132
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

644 Views
4 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs